BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating Once-Daily Extended-Release Formulation of Camlipixant in Comparison to Twice-Daily Immediate Release Formulation - Seite 3
Source: BELLUS Health Inc.
Lesen Sie auch
View source version on businesswire.com: https://www.businesswire.com/news/home/20230405005361/en/
The BELLUS Health Stock at the time of publication of the news with a fall of -8,96 % to 6,35USD on Tradegate stock exchange (05. April 2023, 13:00 Uhr).
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte